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Abstract 
In order to investigate human NK cell reactivity in vivo we have reconstituted human 
immune system components by transplantation of human hematopoietic progenitor cells 
into NOD-scid IL2Rnull mice. We demonstrate here that this model allows the 
development of all NK cell subsets that are also found in human adult peripheral and 
cord blood, including NKp46+CD56- NK cells. Similar to human cord blood, NK cells from 
these reconstituted mice require pre-activation by IL-15 to reach the functional 
competence of human adult NK cells. Mainly the terminally differentiated CD16+ NK cells 
demonstrate lower reactivity without this stimulation. After pre-activation, both CD16+ 
and CD16- NK cells efficiently produce IFN- and degranulate in response to stimulation 
with NK cell susceptible targets, including K562 erythroleukemia cells. NK cell lines, 
established from reconstituted mice, demonstrate cytotoxicity against this tumor cell line. 
Importantly, pre-activation can as well be achieved by bystander cell maturation via poly 
I:C stimulation in vitro and injection of this maturation stimulus in vivo. Pre-activation in 
vivo enhances killing of HLA class I negative tumor cells after their adoptive transfer. 
These data suggest that a functional, but resting NK cell compartment can be 
established in immune compromised mice after human hematopoietic progenitor cell 
transfer.  
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Introduction 
NK cells are innate lymphocytes that are primarily thought to curb viral infections and 
tumor cell expansion until antigen-specific adaptive immune responses can be primed to 
eradicate these threats to human health (1). In contrast to adaptive lymphocytes like T 
and B cells, NK cells recognize their targets through germ line encoded receptors. These 
receptors transmit either activating or inhibitory signals (2-3). The activating receptors 
recognize primarily stress induced molecules on infected and transformed cells, 
including MHC class I like molecules that serve as ligands for the activating NK cell 
receptor NKG2D, PVR and Nectin-2 as ligands for the activating NK cell receptor 
DNAM-1, and B7-H6 as well as ligands of still poorly defined identity for the natural 
cytotoxicity receptors (NCRs) NKp30, NKp46 and NKp44 (4-5). Ligands for these 
activating receptors are up-regulated upon for example DNA damage or heat shock (6-
7), but are also constitutively present on some hematopoietic cells, including myeloid 
dendritic cells (8), microglia (9) and activated macrophages (10). These activating 
signals are balanced by inhibitory receptor engagement, recognizing classical and non-
classical MHC class I molecules. In humans, killer immunoglobulin-like receptors (KIRs) 
recognize polymorphic determinants of classical MHC class I molecules, and C-type 
lectin receptors like the CD94/NKG2 heterodimer engage the non-classical MHC class I 
molecule HLA-E (11). The balance of transmitted activating and inhibitory signals 
decides if NK cells will mount effector functions against conjugated target cells. 
 The main effector characteristics of NK cells are cytokine secretion and 
cytotoxicity (12), and humans carry NK cell subsets that preferentially mediate one or the 
other of these functions. CD56brightCD16-KIR- NK cells respond primarily with production 
of IFN-, TNF and GM-CSF to activation, and only exert cytotoxicity after prolonged 
activation (13). In contrast, CD56dimCD16+KIR+ NK cells are constitutively loaded with 
perforin and granzymes and are the primary human cytotoxic NK cell subset (14). While 
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the latter population constitutes the majority of peripheral blood NK cells, CD56brightCD16-
KIR- NK cells are enriched in human secondary lymphoid organs (15-16). They have 
been proposed to limit pathogen invasion and polarize adaptive immune responses at 
these sites (12, 17). Thus cytotoxic NK cells patrol primarily the periphery, while 
immunoregulatory NK cells support Th1 polarization in secondary lymphoid organs. 
 The developmental pathways leading to the functionally distinct human NK cell 
subsets are still being defined (18). So far three alternative pathways have been 
proposed. Originally, it was proposed that NK cells develop exclusively in the bone 
marrow from which they populate the periphery as constitutively reactive innate 
lymphocytes (1). After the discovery that the immunoregulatory human NK cells could 
acquire phenotypic and functional characteristics of cytotoxic NK cells (19-22), it was 
proposed that CD56brightCD16-KIR- NK cells could home to secondary lymphoid tissues 
by virtue of their CD62L and CCR7 expression and mature to CD56brightCD16+KIR+ NK 
cells at these sites (23). Alternatively, CD56brightCD16-KIR- NK cells might also develop 
directly from CD34+ precursors in secondary (24) or primary lymphoid organs (25).  In 
order to shed some more light on the requirements for the development of the human 
NK cell subsets and their functional competence, we investigated human NK cell 
compartments reconstituted from CD34+ hematopoietic stem and progenitor cells in 
NOD-scid IL2Rnull (hu-NSG) mice in comparison to human cord blood and adult blood 
NK cells. We describe here that both hu-NSG and cord blood NK cells require pre-
activation by monokines to reach functional competence as found in adult peripheral 
blood, and part of this recruitable activity lies dormant in terminally differentiated CD16+ 
NK cells. 
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Material and Methods: 
Preparation of humanized mice 
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice were obtained from the Jackson Laboratory 
(Bar Harbor, ME) and raised under specific pathogen free (SPF) conditions. Human fetal 
liver was obtained from Advanced Bioscience Resources, CA.  The tissue was minced 
and treated with 2 mg/ml collagenase D (Roche Diagnostics, IN) in HBSS with 
CaCl2/MgCl2 for 30 minutes at room temperature followed by filtering through 70 m 
nylon cell strainers (BD Biosciences, CA).  CD34+ human hematopoietic stem and 
progenitor cells (HPCs) were isolated using the direct CD34 MicroBead Kit (Miltenyi 
Biotec, CA).  2-5 days old NSG mice were irradiated with 100 cGy and injected intra-
hepatically with 1-2 x 105 CD34+ HPCs 6 h post irradiation.  The mice were bled 10-12 
weeks post engraftment and peripheral lymphocytes were analyzed by FACS as 
described previously (26-27) to check for the reconstitution of the human immune 
system. Animal protocols were approved by the Institutional Animal Care and Use 
Committee of the Rockefeller University and the Cantonal Veterinary Office Zürich. 
 
Isolation of blood mononuclear cells  
Peripheral blood (PB) from healthy adult volunteers was obtained as part of Institutional 
Review Board-approved protocols from the New York, Liguria and Zürich Blood Centers. 
Human cord blood (CB) samples were kindly provided by the Liguria Cord Blood Bank 
(San Martino Hospital, Genoa, Italy) after delivery of the infant and after prior need for 
clinical samples had been satisfied. Samples were collected from full term mothers upon 
their informed consent for research purpose, according to the declaration of Helsinki. 
Cord blood was processed within 16 h after birth to secure viability of cells. Cord Blood 
and peripheral blood were diluted 1:4 or 1:2 with PBS, respectively, and mononuclear 
cells (CBMCs/PBMCs) were isolated by density-gradient centrifugation on 
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Ficoll/Hypaque. Cells were either directly analyzed or cryopreserved for further analyses. 
Purified NK cells were obtained by negative selection using NK Cell Isolation Kits 
(Miltenyi Biotec). 
 
Isolation of cells from tissues of hu-NSG mice 
For isolation of cells from spleen and lung, organs were minced and treated with 2 mg/ml 
collagenase D in HBSS with CaCl2/MgCl2 for 30 minutes at RT followed by filtering 
through 70 m nylon cell strainers. Livers of mice were perfused with PBS to remove 
blood for the isolation of liver-resident cells and subsequently single cell suspensions 
were generated as described for spleen and lung. Single cell suspensions from lymph 
nodes were generated by meshing the organs through 70 m nylon cell strainers. 
Contaminating erythrocytes in cell suspensions were lysed using ACK lysis buffer or 
removed by density-gradient centrifugation on Ficoll/Hypaque, and remaining cells were 
washed, and subjected to subsequent analysis and functional assays. Purified NK cells 
were obtained by negative selection using NK Cell Isolation Kits, supplemented with 
anti-mouse CD45 antibodies (Miltenyi Biotec). 
 
Generation of polyclonal NK cell lines 
In order to generate polyclonal NK cells from mice with reconstituted human immune 
system components, murine cells were depleted from splenocytes using anti-mouse 
CD45 microbeads und human cells were subsequently cultured in medium with 100 
IU/ml of IL-2. Cells were split upon becoming confluent and medium was replaced. After 
two weeks cell cultures contained >95% human NK cells (hCD45+NKp46+) as analyzed 
by flow cytometry.   
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Degranulation assay 
To characterize the functional capacities of NK cells within bulk cell populations, we 
stimulated bulk cells (splenocytes, cord blood mononuclear cells, peripheral blood 
mononuclear cells, respectively) with target cells at an effector to target ratio of 1:1 for 6 
h in the presence of anti-CD107a antibody. To detect spontaneous degranulation and 
cytokine production, a control without target cells was included. After 1 h, monensin 
(Sigma-Aldrich, 1µg/ml) was added to all samples. At the end of the incubation, cells 
were stained on ice with antibodies against human CD45, CD3, and NKp46, washed, 
fixed, permeabilized, and finally labeled with an anti-IFN- antibody. Cells were 
subsequently analyzed by flow cytometry. 
 
Cytotoxicity assay 
To evaluate the cytotoxic activity of NK cells against the K562 target cell line, cytotoxicity 
assays were performed, as previously described (16). Briefly, target cells were labeled 
with PKH26 (Sigma-Aldrich), and then incubated with NK cell lines at the indicated 
effector/target ratios. After 4 h, cells were harvested; TO-PRO-3-iodide, a membrane-
impermeable DNA stain, was added to each culture (0.5 µM final concentration); and 
cells were finally analyzed by flow cytometry. Background and maximum TO-PRO-3-
iodide staining were obtained by incubation of target cells with medium and detergent, 
respectively. The percent specific lysis was calculated as ((% TO-PRO-3-iodide+PKH26+ 
cells in effector/target cell co-culture  - % TO-PRO-3-iodide+PKH26+ cells in medium)/(% 
TO-PRO-3-iodide+PKH26+ cells in detergent - % TO-PRO-3-iodide+PKH26+ cells in 
medium) x 100%. 
 
In vivo cytotoxicity assay 
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LCL721.221 and LCL721.45 were grown in RPMI, 10% FCS and Penicillin/Streptomycin 
supplemented with L-Glutamine. After labeling with 5 µM CFSE for 10 min at RT, the 
reaction was stopped by the addition of FCS, cells washed twice in PBS and 5 x 106 
cells of both lines injected intravenously into the tails of hu-NSG mice either with or 
without pre-treatment with 50 µg poly I:C by intraperitoneal injection 18h before. Single 
cell suspensions of recipient spleens were analyzed 12 h post-transfer after being 
stained with APC-conjugated anti-HLA class I (w6/32, BioLegend) for the presence of 
CFSE positive cells.  Specific lysis was as calculated by gating on CFSE positive cells 
as (% MHC class I positive - % MHC class I negative) x 100 / % MHC class I positive. 
 
Adoptive transfer of purified NK cell populations 
CD3-NKp46+CD56- cells from pooled spleens of hu-NSG mice were sorted to high purity 
(>98%) on a FACS Aria (BD Biosciences) and labelled with 5 µM CFSE. 1-2 x 105 of 
sorted cells were adoptively transferred into recipient hu-NSG mice (reconstituted with 
same CD34+ HPCs as donor hu-NSG mice), which were sacrificed 48 h later. Recovered 
NKp46+CFSE+ cells from spleens were then analyzed for CD56 expression by flow 
cytometry. 
 
Monoclonal Antibodies and Flow Cytometry  
Analysis of cell surface markers was performed using the following mAbs: V450-
conjugated anti-CD45 (clone HI30), FITC- or PerCP-conjugated anti-CD3, APC-
conjugated anti-NKp46, PE-Cy7-conjugated anti-CD56, APC-Cy7-conjugated anti-CD16 
and FITC- or PE-conjugated anti-CD107a (BD PharMingen, San Diego, CA), FITC-
conjugated anti-CD19, PE-conjugated anti-CD158a,h, PE-conjugated anti-CD158b1/b2,j, 
PE-conjugated anti-CD127 and PE-conjugated anti-NKp46 (Immunotech-Coulter, 
Fullerton, CA), Alexa Fluor® 647 conjugated anti-CD107a (eBioscence), APC-
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conjugated anti-CD56, PE-conjugated CD117, FITC-conjugated anti-CD16 and FITC-
conjugated anti-CD3, were from Miltenyi Biotech (Bergisch Gladbach, Germany). The 
unlabelled anti-NKp46 mAb (clone BAB281) was generously provided by Prof M.C. 
Mingari’s lab. Direct immunofluorescence staining was performed diluting fluorochrome-
labeled mAb with 1 mg/mL human -globulin (human therapy grade from Biotest S.R.L., 
Milan, Italy), to block non-specific FcR binding. Cells were then washed and flow 
cytometric analysis was performed. For indirect immunofluorescence staining, the Alexa 
Fluor® 633-conjugated isotype specific goat anti-mouse Ab (eBioscence) was used. 
Negative controls included directly labelled and unlabelled isotype-matched irrelevant 
mAbs. IFN- expression analysis were performed by PE-conjugated reagents (BD 
Biosciences-PharMingen) or Pacific Blue anti-human IFN- antibody (BioLegend, San 
Diego, CA) after cells were fixed in 2% paraformaldehyde and permeabilized with 0.1% 
saponin. 
 
Statistical Analysis 
Statistical analyses were performed using the Graph-Pad Prism v. 4.00 for Windows 
(GraphPad Software, San Diego, CA). Statistical significance was evaluated by two-
tailed Student t-test. 
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Results 
NOD-scid IL2Rnull mice reconstitute human NK cells from CD34+ hematopoietic 
progenitor cells 
In order to reconstitute human immune system components in NSG mice, we injected 
mice neonatally with 105 human CD34+ hematopoietic stem and progenitor cells 
intrahepatically (27-28). After three month we monitored human B cell, T cell, monocyte, 
dendritic cell and NK cell reconstitution. As previously reported (27) around 60-80% of 
mononuclear splenocytes were of human origin at this timepoint. Of these 50-60% were 
B cells, 25-30% were T cells (CD4:CD8 ratio 3:2), 1-2% were plasmacytoid dendritic 
cells (DCs), 1-2% were conventional DCs, 3-5% were monocytes and 1-3% were NK 
cells. We decided to characterize the human NK cell distribution further. Compared to 
spleen, we found higher percentages of CD3-NKp46+ NK cells in lung, blood and liver, 
while below 1% of mononuclear cells of the bone marrow were NK cells (Figure 1A and 
B). In lung, the organ with the highest NK cell fraction, up to 7% NK cells were detected. 
However, when taking total cell numbers for these organs into account, spleen and liver 
constituted the largest NK cell reservoirs after reconstitution (Figure 1C). These data 
suggest that human NK cells reconstitute in NSG mice with human immune system 
components (hu-NSG), and they are present in all strongly blood perfused organs. 
 
Hu-NSG mice and cord blood contain a NKp46+CD56- NK cell subset 
In order to characterize the NK cell subsets that were developing in hu-NSG mice we 
performed phenotyping of the splenic NK cell compartment. We found KIR, CD94, 
NKG2D, NKp46, NKG2A and CD16 expression on splenic CD3-CD56+ NK cells (Figure 
2A). In comparison to human spleen, whose NK cell compartment is in the majority 
composed of CD56dimCD16+ NK cells (75%) (16), the minority of hu-NSG derived splenic 
NK cells belonged to this terminally differentiated subset (25-40%), suggesting a more 
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immature NK cell compartment in hu-NSG mice compared to human adult spleen. 
Interestingly, in addition to CD56brightCD16- and CD56dimCD16+ NK cells, hu-NSG spleen 
contained a large subpopulation of NKp46+CD56- NK cells (Figure 2B). Part of these 
carried in addition to NKp46 other NK cell markers like NKG2A and CD16. Some of the 
NKp46+CD56-CD16+ NK cells expressed KIRs (20-30%), while minimal or no KIR 
expression was detected on CD16- NK cells (Figure 2C). Vice versa, a subset of CD3-
NKp46+CD56-CD16- cells stained positive for CD127 and CD117, and could therefore 
constitute stage 3 NK cell precursors (29). Since CD56 is up-regulated during human NK 
cell activation (30), we considered the possibility that the NKp46+CD56- NK cells might 
be a resting NK cell population prior to a history of pathogen exposure. In order to 
provide more evidence for this hypothesis, we investigated human cord blood in order to 
determine if this NK cell subpopulation also existed prior to human pathogen exposure. 
Indeed, we found within NKp46+ cord blood NK cells both CD56 and CD16 negative 
cells (Figure 2D). The frequency of these NKp46+CD56- NK cells was in contrast very 
low in adult blood (around 3%). NKp46+CD56- NK cells constituted around 15% of cord 
blood NK cells amounting in some cord blood samples to up to 30% of the human NK 
cell compartment (Figure 2E). In order to determine if indeed these CD3-NKp46+CD56- 
cells can differentiate into CD3-NKp46+CD56+ NK cells, we adoptively transferred 
purified and CFSE labeled CD3-NKp46+CD56- cells into hu-NSG mice reconstituted with 
autologous CD34+ HPCs by intravenous injection. After 48 h, NKp46+CFSE+ cells were 
recovered from recipient spleens and analyzed for their CD56 expression (Figure 2F). All 
recovered cells had up-regulated CD56. Similarly, CD3-NKp46+CD56- cells from hu-NSG 
mice up-regulated CD56 after activation in vitro (Supplemental Figure 1). These data 
suggest that spleens of recently reconstituted hu-NSG mice and human cord blood 
contains a NKp46+CD56- NK cell population that constitutes around 50% of NK cells in 
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hu-NSG mice and up to 30% of NK cells in human cord blood, and can differentiate into 
NKp46+CD56+ NK cells in vitro and in vivo. 
 
NK cells from hu-NSG mice have a decreased ability for cytotoxicity and IFN- 
production compared to NK cells from human adults 
The functional capacity of NK cells from hu-NSG mice was evaluated by ex vivo 
stimulation with two NK cell susceptible human target cell lines, the erythroleukemia cell 
line K562 and the T cell lymphoma line CEM, as well as by monokine stimulation (IL-
12+IL15). While K562 is recognized by a combination of NCR, NKG2D and DNAM-1 
mediated mechanisms, triggering all NK cell subsets, CEM mediated stimulation of NK 
cells is primarily mediated by NKG2D and affects mainly CD56brightCD16- NK cells (31). 
As a surrogate marker for cytotoxicity, degranulation of NK cells in response to these 
stimuli was assessed by CD107a staining and intracellular IFN- staining was monitored 
as a representative measure for cytokine production (Figure 3A). NK cells from hu-NSG 
mice degranulated slightly less than human adult peripheral blood NK cells in response 
to K562 cells. Strikingly, a nearly tenfold difference, was, however, seen in IFN- 
production in response to K562 cells (Figure 3B). Interestingly, NKG2D mediated 
recognition of CEM was similar between NK cells from hu-NSG mice and human adult 
blood. When we analyzed K562 recognition by the different NK cell subsets of hu-NSG 
mice, the functional defect was primarily confined to CD56dim and NKp46+CD56- NK cells 
(Figure 3C). Similarly, NK cells from cord blood degranulated less efficiently in response 
to K562 than human adult blood NK cells, and this deficiency was primarily confined to 
CD56dim and NKp46+CD56- NK cells (Figure 3D). The same NK cell subsets also 
produced less IFN-, when restimulated with K562 cells (data not shown). These data 
suggest that the resting NK cell compartment of hu-NSG mice degranulate and produce 
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cytokines less efficiently upon cognate target recognition than human adult NK cells, and 
part of this deficiency is caused by the CD56dim and NKp46+CD56- NK cell populations. 
 
IL-15 mediated pre-activation can overcome the functional deficiency of NK cells 
from hu-NSG mice 
Since NK cell pre-activation by mature DCs has recently been identified as crucial for full 
functional capacity of these innate lymphocytes (8, 32-35), we exposed hu-NSG 
splenocytes to the monokines IL-12 and IL-15 as well as the DC maturing TLR3/mda5 
ligand polyinosinic:polycytidylic acid (poly I:C or p(I:C)). Degranulation in response to 
K562 and CEM was markedly enhanced by IL-15 or poly I:C pre-activation (Figure 4A). 
In addition, IFN- production by hu-NSG NK cells after stimulation with K562 and CEM 
was boosted five- to tenfold after pre-activation with IL-15 or poly I:C in vitro (Figure 4B). 
Poly I:C was only able to enhance degranulation and IFN- production by NK cells, when 
bystander cells, presumably mainly DCs, were present, while purified NK cells from hu-
NSG mice or cord blood only increased their degranulation and cytokine production in 
response to K562 after pre-activation with IL-15, but not poly I:C (Figures 4C to F). From 
these data we conclude that NK cells from hu-NSG mice and cord blood have a similar 
functional capacity as human adult blood NK cells, but require pre-activation to respond 
efficiently to cognate target cells, while adult NK cells have a higher constitutive 
reactivity, possibly due to pre-activation by environmental stimuli.  
 
Pre-activation increases perforin and granzyme B content in NK cells of hu-NSG 
mice 
In addition to the functional parameters of degranulation and IFN- production, we also 
tested if the cytotoxic armament of hu-NSG NK cells increased upon pre-activation in 
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vitro. For this purpose we stained intracellularly for perforin and granzyme B in CD3-
NKp46+ NK cells of hu-NSG splenocyte cultures that had been exposed to poly I:C or 
the monokines IL-12 and IL-15. Both IL-15 and poly I:C addition were able to increase 
the perforin and granzyme B content of hu-NSG mice around fivefold (Supplemental 
Figure 2A and B). Analogous to the in vitro activation data, the frequency of perforin 
expressing cells was only increased after IL-15 stimulation of purified splenic NK cells, 
while poly I:C was not able to induce cytotoxic granules directly (Supplemental Figure 
2C). Therefore, pre-activation of NK cells via bystander cell maturation with poly I:C or 
direct stimulation by IL-15 increases both degranulation capacity and cytotoxic effector 
molecule expression of NK cells from hu-NSG mice. 
 
Pre-activation boosts degranulation and cytokine production in terminally 
differentiated NK cells of hu-NSG mice 
Since we had noted that primarily CD56dim and NKp46+CD56- NK cells of hu-NSG mice 
and cord blood were functionally deficient in comparison to adult peripheral blood NK 
cells, we wondered if IL-15 mediated pre-activation would affect these NK cell 
compartments. We confirmed that these NK cell compartments of hu-NSG mice 
contained CD16+KIR+ terminally differentiated human NK cells (Figure 5A and B), and 
that CD16 expression was not altered on purified NK cells from these subsets during 
one day of IL-15 activation, while CD56 was up-regulated during this activation period 
(Supplemental Figure 1 and data not shown). This allowed us to analyze degranulation 
and cytokine production of CD16+ terminally differentiated hu-NSG NK cells in response 
to K562 stimulation after IL-15 pre-activation. Indeed, degranulation and IFN- 
production by these NK cells were significantly, around 5 fold, elevated after pre-
activation in response to K562 stimulation (Figure 5C and D). In addition, CD16- NK cells 
also up-regulated IFN- production and degranulation in response to K562 cells after 
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exposure to IL-15. Thus, the functional deficiency of terminally differentiated NK cells in 
hu-NSG mice can be overcome by pre-activation with IL-15. 
 
NK cells from hu-NSG mice display cytotoxic function against K562 cells 
So far we tested degranulation and cytotoxic molecule expression as surrogate markers 
for NK cell cytotoxicity of hu-NSG mice. In order to demonstrate cytotoxicity against 
K562 cells by human reconstituted NK cells from hu-NSG mice directly, we established 
NK cell lines from hu-NSG mice (Figure 6A). These lines contained to more than 95% 
NKp46+ NK cells with partial KIR expression. They were comparable or slightly superior 
to a NK cell lines established from adult human blood with respect to perforin and 
granzyme B expression. We used the To-Pro-3 incorporation assay as a measurement 
of direct cytotoxicity (9, 16, 36). The NK cell lines from hu-NSG mice killed K562 with 
high efficiency of more than 70% lysed cells already at a 10:1 NK:K562 ratio (Figure 6B). 
This suggests that NK cells from hu-NSG mice are functionally competent, but require 
cytokine pre-activation to reach their full functional potential. 
 
Poly I:C administration enhances human NK cell functions in vivo 
The above described experiments documented the composition and functions of NK 
cells from hu-NSG mice ex vivo and after activation in vitro. However, in order to assess 
the capacity of these innate lymphocyte to become functional effectors in vivo, we 
injected poly I:C intraperitoneally. 18 h after injection, hu-NSG mice were sacrificed and 
degranulation as well as intracellular IFN- content of CD3-NKp46+ splenocytes was 
assessed ex vivo or after restimulation with monokines or the NK cell susceptible cell 
lines K562 and CEM. Already ex vivo, NK cell demonstrated low levels of CD107a 
staining and intracellular IFN- content (Figure 7A, B and C). Moreover, they responded 
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with three fold better degranulation and five- to tenfold increased IFN- production to 
restimulation with K562 and CEM (Figure 7B and C). In addition, when we adoptively 
transferred CFSE labeled HLA class I deficient LCL721.221 cells alongside their 
parental HLA class I positive LCL721.45 cells into hu-NSG mice, LCL721.221 cells were 
killed in vivo within 12 h, and this cytotoxicity was enhanced by prior poly I:C injection 
(Figure 7D and E). Cytolysis of LCL721.221 increased from 40 to 85% upon NK cell pre-
activation in vivo. These data document that NK cells from hu-NSG mice can be rapidly, 
within 18 h, pre-activated by poly I:C injection in vivo. This should allow the study of 
human NK cell functions against viral infections and tumors in vivo in hu-NSG mice. 
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Discussion 
Our study assessed human NK cell reconstitution from CD34+ hematopoietic stem and 
progenitor cells in NOD-scid IL2Rnullmice (NSG). We found reconstitution of NK cell 
subsets that are similar to human cord blood, differing by the additional presence of 
NKp46+CD56- NK cells from the subpopulations found in human adult blood. 
Functionally, these reconstituted NK cell populations also resembled the lower 
spontaneous NK cell activity found in cord blood, secreting lower levels of IFN- and 
degranulating less efficiently in response to susceptible tumor cell lines like K562. This 
deficiency was primarily found in terminally differentiated CD56dimCD16+ NK cells, the 
main cytotoxic NK cell compartment in humans. However, cord blood and reconstituted 
NSG mouse NK cells could be pre-activated directly with IL-15 or indirectly via poly I:C 
mediated bystander cell maturation in vitro and in vivo to reach cytotoxicity and cytokine 
secretion levels similar or exceeding human adult peripheral blood NK cells. These 
findings suggest that resting NK cells with a similar composition as human cord blood 
NK cells can be reconstituted in hu-NSG mice, and are functionally competent with 
respect to mounting NK cell effector functions after pre-activation. 
 The human NK cell reconstitution in hu-NSG mice is with respect to NK cell 
subset distribution similar to human NK cell development in BALB/c Rag2-/- c-/- mice 
(22), in which also NKp46+CD56-, CD56brightCD16-KIR-and CD56dimCD16+KIR+ NK cell 
populations could be observed. Interestingly, however, in all investigated organs except 
for bone marrow, the frequency of developing NK cells was five- to tenfold lower in 
reconstituted BALB/c Rag2-/- c-/- versus hu-NSG mice (22, 37). This suggests that while 
NK cell development in the bone marrow progresses to similar levels in these two 
immunodeficient mouse strains, human NK cells survive and, therefore, accumulate to 
higher levels in NSG mice. The lower myeloid xenoreactivity mediated by cross-reactivity 
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of NOD SIRP- towards human CD47 (38) could be in part responsible for this better NK 
cell reconstitution. However, human NK cells in BALB/c Rag2-/- c-/- mice were able to 
delay K562 tumor growth in vivo (39) and can be expanded in BALB/c Rag2-/- c-/- mice 
by IL-15 or IL-15/IL-15R hybrid molecule administration, reaching then levels of steady-
state NK cell reconstitution in NSG mice (22). This expansion occurs at the expense of 
the CD16 negative NK cell subsets and converts nearly all NK cells to CD16+ partially 
KIR+ NK cells. A similar NK cell expansion could also be induced in reconstituted NSG 
mice by hydrodynamic delivery of IL-15 encoding expression plasmids, but the effect on 
NK cell subset differentiation was not investigated in detail in this study (40). Therefore, 
we propose that the more efficient NK cell subset reconstitution in hu-NSG mice 
recommends this model for studying immune responses mediated by these human 
innate lymphocytes in vivo. 
 In addition to this essential role of IL-15 for NK cell development and 
accumulation, which was also previously reported for mouse NK cells (41-42), IL-15 has 
also been shown to be required for pre-activation of mouse NK cells to reach their full 
functional potential (35). During viral and bacterial infections this NK cell pre-activation is 
performed by DCs, possibly via IL-15 trans-presentation (35). Similarly in humans, DCs 
can activate NK cells to produce cytokines, proliferate and acquire elevated cytotoxicity 
(8, 32-33, 43-45). Thus reconstituted human NK cells of hu-NSG mice resemble resting 
NK cells, which like mouse NK cells from animals housed under pathogen free 
conditions, require pre-activation to become fully functional. In contrast, human adult NK 
cells display a higher constitutive reactivity, because they are probably partially pre-
activated through continuous pathogen encounter. Especially the CD56dimCD16+ NK 
cells required this pre-activation step, while CD56brightCD16- NK cells demonstrated 
already significant reactivity against K562 cells ex vivo, quite similar to CD56brightCD16- 
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NK cells from human adult blood. These findings are consistent with a previous report, 
which also suggested that deficiency in NK cell reactivity of human cord blood was 
primarily confined to CD56dimCD16+ NK cells (46). This suggests that primarily terminally 
differentiated human NK cells require pre-activation. We also identified IL-15 as a potent 
mediator of human NK cell pre-activation in hu-NSG mice, and poly I:C mediated 
maturation for NK cell pre-activation probably primarily affected also human DCs to fulfill 
this function. Indeed, we have previously shown that poly I:C mediated DC maturation 
renders these cells more efficient in NK cell stimulation than other maturation stimuli 
(47), and these DCs can interact with both CD56brightCD16- and CD56dimCD16+ NK cells 
to transmit IL-15 dependent signals (48). Thus, hu-NSG mice with reconstituted human 
immune system compartments should allow studies on resting human NK cells, which 
are functionally competent.  
 The functional competence that we observed after pre-activation, also questions 
further the requirement of NK licensing by somatic tissues for reactivity of this innate 
lymphocyte subset (49-50). Licensing describes functional competence of NK cells that 
sequentially up-regulate inhibitory NK cell receptors during development until they 
express at least one for a self MHC class I molecule. This model is supported by several 
lines of evidence. Firstly, transgenic expression of an inhibitory receptor decreases the 
frequency of NK cell expression for other inhibitory receptors, but only in the presence of 
the cognate MHC class I molecule (51). Secondly, NK cells that do not express self 
MHC reactive inhibitory receptors are functionally attenuated (52-53). Thirdly, NK cells of 
TAP deficient patients that do not express MHC class I molecules at high levels on their 
cell surfaces due to defective peptide loading are functionally compromised (54-55). In 
contrast, during mouse cytomegalovirus (MCMV) infection, primarily unlicensed NK cells 
without an inhibitory receptor for polymorphic self MHC class I molecules restrict virus 
load (50), and unlicensed NK cells acquire functional competence after cytokine 
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activation (56). Likewise, NK cells lacking inhibitory receptors specific for MHC class I 
molecules are activated after Listeria monocytogenes infection in vivo, and then produce 
as much IFN- as NK cells carrying these inhibitory receptors (52). Considering these 
different possibilities, the functional competence of reconstituting human NK cells in hu-
NSG mice suggests that licensing can either occur via inhibitory NK cell receptor 
engagement (CD94/NKG2A or KIR) by HLA class I molecules on reconstituting 
hematopoietic cells, in addition to previously investigated stromal cells (57), or that 
unlicensed NK cells can gain similar functionality as licensed human adult blood NK cells 
after pre-activation in vivo. Further studies on the influence of transgenic HLA class I 
expression in hu-NSG mice might yield valuable insights into this NK cell development 
question.  
 Altogether, our data point towards functional competence of resting human NK 
cells that develop from CD34+ hematopoietic stem and progenitor cells in hu-NSG mice. 
We propose that this model could allow the study of NK cell responses during infection 
with lymphotrophic human pathogens like the Epstein Barr virus (27). These studies 
could reveal the contribution of NK cells to initial pathogen restriction and priming of 
protective immune control. Such information could then be harnessed to develop 
vaccination approaches against human pathogens. 
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Figure legends 
Figure 1: Distribution of human NK cells in reconstituted NSG mice. Frequency 
within human CD45 positive cells and total number of CD3-NKp46+ human NK cells in 
spleen, blood, lung, liver and bone marrow (BM) of NSG mice reconstituted with human 
immune system components three month after transfer of CD34+ hematopoietic 
progenitor cells. Representative flow cytometric staining from one mouse (A) and 
composite data from 7 mice (B and C) are shown. Numbers in plots represent 
frequencies within gates. 
 
Figure 2: NK cell subset development in NSG mice in comparison to human adult 
and cord blood. CD3-CD56+ human NK cells from spleens of reconstituted NSG mice 
were analyzed for KIR, CD94, NKG2D, CD16, NKG2A and NKp46 expression (A). One 
representative of 12 mice is shown. CD3-NKp46+ human NK cells from spleens of 
reconstituted NSG mice were analyzed for CD56, CD16 and NKG2A expression (B). A 
representative staining from one of 12 mice is shown. CD16, KIR, CD127 and CD117 
expression on CD3-NKp46+CD56- cells of hu-NSG mice was analyzed (C). One 
representative out of 3 stainings is displayed. In comparison, CD56 and CD16 
expression was analyzed on CD3-NKp46+ NK cells from human adult (PB) and cord 
blood (CB). One representative example (D) and composite data (E) of 8 experiments 
are shown. CFSE labeled CD3-NKp46+CD56- cells of hu-NSG mice were adoptively 
transferred into hu-NSG mice, which had been reconstituted with autologous CD34+ 
HPCs. CD56 expression on the recovered NKp46+ CFSE labeled cells from recipient 
spleens was analyzed after 48 h by flow cytometry (F). Gray shaded histogram of post-
sort CD3-NKp46+CD56- cells in comparison to black histogram of post-sort CD56+ (left 
panel). White histogram of recovered cells in comparison to gray shaded histogram of 
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cells that were transferred (right panel). One representative of 2 experiments is shown. 
Numbers in plots represent frequencies within gates or quadrants. 
 
Figure 3: Functional activity of human NK cells from reconstituted NSG mice in 
comparison to human adult or cord blood NK cells. Degranulation, a surrogate 
marker for cytotoxicity, and cytokine production were assessed by surface CD107a and 
intracellular IFN- staining in response to ex vivo stimulation with medium, the 
erythroleukemia cell line K562, the T cell lymphoma cell line CEM and the monokines IL-
12 plus IL-15 (IL-12/15). One representative staining (A) and composite data (B) of 12 
mice in three experiments are shown. In the composite data human NK cell reactivity of 
reconstituted NSG spleens was compared to three adult PBMC samples. In addition, the 
function of the human NK cell subsets CD56brightCD16-, CD56dimCD16+ and 
NKp46+CD56- from human adult (PBMC), hu-NSG (C) mice or cord blood (CBMC in D) 
were compared for degranulation. Composite data of 3 (C) and 6 (D) experiments are 
shown. Numbers in plots represent frequencies within gates. 
 
Figure 4: Pre-activation enhances human NK cell function in spleen cells from 
reconstituted NSG mice and human cord blood. Splenocytes from reconstituted NSG 
mice (A and B) purified NK cells from hu-NSG mice (C and D) and human cord blood (E 
and F) were used untreated (Medium) or pre-activated with poly I:C (p(I:C)) or the 
monokines IL-12 and IL-15. These cultures were restimulated with medium alone, 
monokines, K562 cells or CEM cells. Degranulation (CD107a; A, C and E) and cytokine 
production (IFN-; B, D and F) were evaluated after gating on NKp46 positive cells. A 
and B represent composite data from 4 mice in two experiments, and C and D from 10 
mice in two experiments and E and F from 3 experiments.  
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Figure 5: Terminally differentiated CD16+ NK cells acquire functional capacity after 
IL-15 mediated pre-activation. Distribution of KIR+ (A) and CD16+ (B) NK cells in 
splenic CD56bright, CD56dim and CD56- NK cell subsets of hu-NSG mice, as gated in the 
upper panels of (A) in comparison to isotype control staining or (B) staining on marker 
negative CD3+ cells (gray shaded histograms). Degranulation (C) and IFN- production 
(D) of unstimulated and pre-activated CD16+ and CD16- NK cells after co-culture with 
K562 cells were analyzed. A representative experiment of 2 is shown in A and B, while C 
and D represent composite data of 2 independent experiments. Numbers in plots 
represent frequencies within gates or marker regions. 
 
Figure 6: Cytotoxic ability of a human NK cell line from reconstituted NSG mice. 
(A) Comparison of NKp46, KIR, perforin and granzyme B (GrzB) expression of a 
reconstituted mouse derived human NK cell line with a line of human adult peripheral 
blood NK cells. (B) Cytotoxicity of the human NK cell line from reconstituted NSG mice 
against K562. Loss of membrane integrity of PKH26 labelled K562 cells as a measure of 
cytotoxicity was assessed by To-Pro-3 iodide staining of DNA, which is blocked by intact 
cell membranes. Cytotoxicity was evaluated at the indicated NK:K562 (E:T) ratios. One 
representative of 6 experiments with three different NK cell lines from three mice is 
shown. Numbers in plots represent frequencies within gates. 
 
Figure 7: Pre-activation of human NK cells of reconstituted NSG mice in vivo. 
Splenocytes of untreated or poly I:C (p(I:C)) injected reconstituted NSG mice were 
restimulated ex vivo with medium alone or the monokines IL-12 and IL-15, or K562 cells, 
or CEM cells. Both degranulation (B) and cytokine production (IFN-; A and C) were 
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evaluated. One representative of two experiments (A) and composite data (B) from eight 
mice are shown. CFSE labeled LCL721.221 (HLA class I negative) and LCL721.45 (HLA 
class I positive) cells were injected intravenously into untreated or poly I:C pre-activeted 
hu-NSG mice. 12 h later the composition of CFSE labeled cells in the recipient spleens 
was analyzed by w6/32 (anti-HLA class I) staining. Analysis of HLA class I expression 
and CFSE prior to adoptive transfer (D) and after recovery after gating on CFSE+ cells 
(E). One representative out of 3 experiments is shown. Numbers in plots represent 
frequencies within gates or marker regions. 
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